礼来公司公布的最新研究数据显示,其药物Omvoh在长期使用过程中的安全性特征与先前已知的安全性数据保持一致。经过长期跟踪观察,未发现任何新的安全性信号。
该结果进一步验证了Omvoh既有的安全性表现,为临床医生和患者提供了长期用药的信心。
礼来公司公布的最新研究数据显示,其药物Omvoh在长期使用过程中的安全性特征与先前已知的安全性数据保持一致。经过长期跟踪观察,未发现任何新的安全性信号。
该结果进一步验证了Omvoh既有的安全性表现,为临床医生和患者提供了长期用药的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.